Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yamoa is a dietary supplement derived from the ground bark of the *Funtumia elastica* tree, also known as the West African silk-rubber tree. It is traditionally used in West Africa for respiratory ailments and is marketed globally for the support of conditions such as asthma and hay fever. The product is composed of 100% pure bark powder and contains active constituents including polysaccharides (specifically the Yam-I fraction), anthocyanins, tannins, and flavonoids. Peer-reviewed research suggests that Yamoa's polysaccharides function by priming gamma-delta T cells and enhancing innate immune responses, which may help modulate allergic respiratory inflammation. It is commercially available in both powder and capsule forms but is not approved by the FDA as a pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yamoa.